Welcome to our dedicated page for Tempest Therapeutics SEC filings (Ticker: TPST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tempest Therapeutics, Inc. (NASDAQ: TPST) SEC filings page on Stock Titan provides investors with direct access to the company’s regulatory disclosures, along with AI-assisted context. Tempest is a clinical-stage biotechnology company headquartered in Brisbane, California, developing small molecule and cell-based therapeutics with tumor-targeted and immune-mediated mechanisms to fight cancer.
Through this page, users can review Tempest’s Form 8-K current reports, which the company uses to announce material events such as equity financings, asset purchase agreements, and leadership changes. For example, Tempest has filed 8-Ks describing registered direct offerings of common stock and concurrent private placements of warrants, as well as an asset purchase agreement to acquire dual-targeting CAR T-cell therapy programs from Factor Bioscience affiliates.
Investors can also use this section to locate Tempest’s periodic reports, such as Forms 10-Q and 10-K, which include detailed financial statements, risk factor discussions, and management’s analysis of its clinical-stage oncology pipeline and capital resources. These filings complement the company’s press releases on quarterly financial results and business updates.
Stock Titan enhances Tempest’s SEC filings with AI-powered summaries that highlight key terms, financing structures, and transaction conditions, helping readers quickly understand complex documents without replacing the full text. The platform also surfaces information on equity issuances, warrant terms, and other securities-related disclosures reported under unregistered sales of equity securities. Real-time updates from the EDGAR system ensure that new TPST filings, including future 10-K, 10-Q, and 8-K reports, appear promptly, allowing investors to track Tempest’s regulatory history and ongoing corporate developments in one place.
Tempest Therapeutics is registering 2,777,781 shares of common stock for resale by selling stockholders pursuant to registration rights granted in a March 20, 2026 private placement.
The registration covers (i) 462,964 issued shares, (ii) 925,927 shares issuable upon exercise of Series A Warrants, (iii) 925,927 shares issuable upon exercise of Series B Warrants, and (iv) 462,963 shares issuable upon exercise of Pre-Funded Warrants. The company will not receive proceeds from resale by the selling stockholders; the company will receive proceeds only from any cash exercise of the Common Warrants and nominal proceeds from cash exercise of the Pre-Funded Warrants. Shares outstanding were 14,344,034 as of March 30, 2026, and the Nasdaq closing price was $1.56 per share on April 8, 2026.
Tempest Therapeutics is registering for resale up to 8,268,495 shares of its common stock issued to sellers in the Asset Purchase Agreement. The registration covers shares issued in connection with the Acquisition and permits the named selling stockholders and their permitted transferees to offer or sell the Shares from time to time.
The prospectus states we will not receive any proceeds from resale by the selling stockholders. The percentage ownership calculations are based on 14,344,034 shares outstanding as of March 25, 2026. Sales may occur in public or private transactions, at prevailing market prices or negotiated prices.
Tempest Therapeutics, Inc. reported that Corporate Controller Justin Trojanowski received a grant of employee stock options for 22,000 shares of common stock. The options have an exercise price of $1.64 per share and expire on March 30, 2036.
According to the vesting terms, 25% of the options will vest on March 31, 2027, with the remaining options vesting in 36 equal monthly installments thereafter, contingent on his continued service. Following this grant, his reported holdings in these options total 22,000 derivative securities, all held directly.
Tempest Therapeutics, Inc. reported that Chief Financial Officer Nicholas Maestas received a grant of employee stock options covering 140,000 shares of common stock at an exercise price of $1.64 per share. These options expire on March 30, 2036 and are held as a direct ownership position.
According to the vesting terms, 25% of the total shares will vest on March 31, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, contingent on Maestas’s continued service. Following this grant, he holds 140,000 options in this award.
Tempest Therapeutics, Inc. received an updated ownership report from several Versant-managed funds on Schedule 13D/A Amendment No. 7. The amendment reflects dilution of their stakes after the company sold additional common shares.
Versant Venture Capital VI, L.P. now reports beneficial ownership of 16,149 shares, or 0.1% of Tempest’s common stock. Versant Vantage II, L.P. reports 162,972 shares, or 1.1%. Versant Venture Capital IV, L.P. reports 90,084 shares, or 0.6%, and Versant Side Fund IV, L.P. reports 567 shares. Versant Ventures IV, LLC reports 90,651 shares, or 0.6%. Percentages are based on 14,344,034 shares outstanding as of March 25, 2026, per Tempest’s Form 10-K.
Tempest Therapeutics, Inc. is registering the resale of up to 2,777,781 shares of its common stock by selling stockholders.
The registration covers shares issued in a March 20, 2026 private placement (including 462,964 issued shares, 925,927 Series A Warrant shares, 925,927 Series B Warrant shares and 462,963 Pre-Funded Warrant shares). The company will not receive proceeds from resale of these shares. Shares outstanding were 14,344,034 as of March 30, 2026.
Tempest Therapeutics, Inc. is registering for resale up to 8,268,495 shares of its common stock on behalf of selling stockholders who received the shares under an Asset Purchase Agreement.
The prospectus states the Shares were issued in connection with the acquisition of CAR-T and related assets from Erigen LLC and Factor Bioscience Inc.; the company will not receive proceeds from resales. The prospectus discloses 14,344,034 shares outstanding as of March 25, 2026 and cites a closing market price of $1.73 per share on March 27, 2026. The registration statement is a shelf Form S-3 registration enabling resale "from time to time" by the named selling stockholders and any permitted transferees.
Tempest Therapeutics, Inc. is a clinical-stage oncology company focused on dual‑targeting CAR‑T cell therapies and first‑in‑class small molecules for difficult cancers and immunology indications.
In February 2026, Tempest closed an all‑stock acquisition of several dual‑targeting CAR‑T programs from Erigen and Factor, issuing 8,268,495 common shares and obtaining global rights outside Greater China, India, Turkey and Russia. Lead CAR‑T asset TPST‑2003, an autologous CD19/BCMA therapy for relapsed or refractory multiple myeloma, has shown early but striking activity, including a 100% complete response rate (6/6) in the REDEEM‑1 Phase 1/2a trial and a 100% overall response rate (25/25) across REDEEM‑1 and an investigator‑initiated trial.
Amezalpat, a selective oral PPARα antagonist for first‑line unresectable or metastatic hepatocellular carcinoma, delivered a six‑month median overall survival improvement (21 vs. 15 months) and a hazard ratio of 0.65 in a randomized global Phase 1b/2 study, and has received FDA orphan drug and Fast Track designations as well as EMA orphan drug status. Tempest plans a pivotal Phase 3 trial via partners, while advancing TPST‑1495 into a National Cancer Institute‑funded Phase 2 study in familial adenomatous polyposis and progressing allogeneic and in vivo CAR‑T candidates. As of March 25, 2026, Tempest had 14,344,034 common shares outstanding and a non‑affiliate equity market value of about $30.1 million as of June 30, 2025.